Vincent O'Neill

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Austin, TX
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Richard Steinhart, as Attorney in Fact for Vincent O'Neill
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Vincent O'Neill

Form 4 holding Executive Vice President, Chief of Product Development and Medical Officer

BioXcel Therapeutics, Inc.

Security class
Common Stock
Shares / value
19,957
Estimated value
$7,031
Report date
16 Dec 2024
Price
$0.3523
Ownership
Direct
Form 4 holding Executive Vice President, Chief of Product Development and Medical Officer

BioXcel Therapeutics, Inc.

Security class
Restricted Stock Units
Shares / value
2,606
Estimated value
$944
Report date
14 Dec 2024
Price
$0.3624
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Executive Vice President, Chief of Product Development and Medical Officer

BioXcel Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
1,875
Estimated value
Report date
22 Jul 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
0

Insider Reports Filed by Vincent O'Neill

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .